InMode Ltd. (NASDAQ:INMD) saw some unusual options trading activity on Wednesday. Investors purchased 8,959 call options on the stock. This is an increase of approximately 167% compared to the typical volume of 3,360 call options.
InMode stock opened at $85.83 on Thursday. The firm has a 50 day simple moving average of $68.92 and a 200-day simple moving average of $53.34. InMode has a 1-year low of $18.02 and a 1-year high of $90.00. The stock has a market cap of $5.49 billion, a price-to-earnings ratio of 57.22 and a beta of 1.65.
InMode (NASDAQ:INMD) last posted its quarterly earnings results on Wednesday, July 28th. The healthcare company reported $0.51 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.27. The business had revenue of $87.33 million during the quarter. InMode had a net margin of 44.34% and a return on equity of 45.87%.
Several brokerages recently issued reports on INMD. TheStreet cut shares of InMode from a “b-” rating to a “c” rating in a research note on Friday, October 1st. Robert W. Baird upped their price objective on shares of InMode from $62.00 to $80.00 and gave the company an “outperform” rating in a research note on Wednesday. Needham & Company LLC dropped their price objective on shares of InMode to $103.00 and set a “buy” rating for the company in a research note on Tuesday. Canaccord Genuity upped their price objective on shares of InMode from $60.00 to $80.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Barclays increased their price target on shares of InMode from $60.00 to $85.00 and gave the company an “overweight” rating in a research note on Wednesday. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, InMode has a consensus rating of “Buy” and a consensus price target of $71.58.
InMode Company Profile
InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies. The company offers minimally-invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments.
Featured Story: High-Yield Dividend Stocks
Receive News & Ratings for InMode Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMode and related companies with MarketBeat.com's FREE daily email newsletter.